Prior treatment with anti-PD-1 or anti-PD-L1 therapeutic antibody, or pathway-targeting agents\r\n* Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met:\r\n** Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose\r\n** No history of severe immune-related adverse effects from anti-CTLA-4 (NCI Common Terminology Criteria for Adverse Events [CTCAE] grade 3 and 4)
Patient has received prior therapy with an anti- programmed death receptor 1 (anti-PD-1), anti-PD-1- ligand-1 (anti-PD-L1), or anti-PD-1 ligand-2 (anti-PD- L2) agent.
Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways); examples include nivolumab, MPDL3280, etc
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Patients may have received prior anti-CTLA4 or other anti-PD-1/anti-PD-L1 therapy, not both, provided that it is completed >= 4 weeks prior to registration
No prior systemic treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways;
Patients must have had prior treatment with anti-PD1 or anti-PD-L1 agents and had documented disease progression either while on these agents or after stopping therapy with these agents without intervening therapy; patients must have discontinued anti-PD-1 or anti-PD-L1 therapy at least 21 days prior to registration
Patients must not have achieved a confirmed partial or complete response to the anti-PD-1 or anti-PD-L1 agents prior to progression
Patients must not have had systemic therapy, excluding anti-PD-1 or anti-PD-L1 agents, within 21 days prior to registration
Patients must not have had:\r\n* Prior treatment with ipilimumab or other CTLA-4 antagonists\r\n* Systemic therapy between progression on the anti-PD-1 or anti-PD-L1 agents and registration\r\n* Note: Systemic therapy (including BRAF-targeting agents) prior to anti-PD-1 or anti-PD-L1 therapy is allowed
Patients must not have had prior immunotherapy with anti-PD-L1, anti-PD-1, anti-CTLA4 or similar drugs; patients must not be planning to receive any of the prohibited therapies during the screening or treatment phases of the study
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents; patients who have received prior treatment with anti-CTLA-4 may be enrolled provided the following requirements are met:\r\n* Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose to randomization\r\n* No history of severe immune-related adverse effects (CTCAE Grade 3 and 4) from anti-CTLA-4
Prior treatment with any PARP inhibitor or any anti-PD-1/anti-PD-L1 antibody
While prior therapy with nivolumab, pembrolizumab, or atezolizumab is allowed, any prior therapy with other anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) is not allowed
Prior treatment with lenvatinib or any PD-1, anti-PD-L1, or anti-PD-L2 agent, excluding melanoma and NSCLC where prior treatment with one PD-1, anti-PD-L1, or anti-PD-L2 agent is allowed
Prior IL-15 treatment or cytotoxic therapy, immunotherapy, radiotherapy, major surgery, antitumor vaccines or monoclonal antibodies in the 4 weeks prior or for checkpoint inhibitors such as anti-CTLA-4 or anti PD1/PD-L1 or nitrosoureas or mitomycin C for 6 weeks prior to C1D1.
No prior therapy with a CDK 4/6 inhibitor; prior anti-PD-1 and anti-PD-L1 therapy is permitted
Prior treatment with immune checkpoint inhibitors (eg, anti-CTLA-4, anti-PD-1, anti-PD-L1, and any other antibody or drug specifically targeting T-cell co-stimulation) or an IDO inhibitor (exception is tumor types in which a PD-1 pathway targeted agent is approved, e.g. melanoma, non-small cell lung cancer.)
Subjects who have received prior therapy with any T cell co-stimulation or checkpoint pathways such as anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, anti-CD137; or other medicines specifically targeting T cells are prohibited. Prior IL-2 is permitted.
6. Part A: Prior exposure to immunotherapy such as but not limited to other anti-CTLA-4, anti-PD-1, or anti-PD-L1 antibodies excluding vaccines. Part B: Exclusion of prior immunotherapy exposure will be limited to anti-PD-1, anti-PD-L1, or anti-PD-L2;
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Received any systemic therapy for cancer treatment including immunotherapeutic agents such as anti-PD1 or anti-PD-L1 antibody therapy.
Has received pembrolizumab, or prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody as part of any previous therapy, including trials
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Subjects previously treated with T cell immune-modulating antibodies, including anti-CTLA-4, anti-PD-1 and/or anti-PD-L1 agents
Patient with melanoma, ovarian cancer, renal cell carcinoma, colorectal cancer, and other solid tumors who have received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PDL2 antibody; melanoma patients who received anti-PD-1 antibodies in the adjuvant setting are allowed to participate as long as their last anti-PD-1 antibody was given at least 6 months prior to their planned start of study therapy
Subject has already received one of the following therapy/treatment: anti-PD-1, anti-PD-L1, or anti-PD-L2 inhibitor.
Patients must not have received prior immuno-oncology regimens, including but not limited to inhibitors such as anti PD-1, anti-PD-L1, anti-PD-L2, anti CD137, or anti CTLA-4 (cytotoxic T lymphocyte-associated protein 4) antibody, or any other antibody or drug specifically targeting T cell co stimulation or checkpoint pathways, indoleamine 2,3-dioxygenase pathway inhibitors, cancer vaccines, adoptive cell therapies, or other cytokine therapies.
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2, or HSP inhibitor
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent; has been on any prior Merck MK-3475 (pembrolizumab) studies
The subject has received prior pembrolizumab or any other anti-PD-1, anti-PD-L1, or anti-PD-L2 therapy, or has participated in any prior studies involving pembrolizumab
Prior treatment with lenvatinib or any anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Patients should be excluded if they have had prior systemic treatment with an anti-CTLA4 antibody and anti-PD1/PDL1 antibody; prior treatment with single agent anti-CTLA4, anti-PD1 or anti-PDL1 antibody is allowed
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent; please contact the principal investigator for further clarification if needed
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 oranti-CTLA-4 antibody
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Subject on prior chemotherapeutic, immunomodulator (such as anti-CTLA-4, anti-PD-1 or anti-PD-L1 inhibitor), investigational, or other therapies for the treatment of cancer must wait at least 28 days after the last dose of these therapies before administration of the first dose of the IMP.
Prior anti-PD-1 or anti-PD-L1 therapy may not be administered after ACT and before study atezolizumab (MPDL3280A) administration
COHORT 1: Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
COHORT 2: Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Prior exposure to an anti-PD-1, anti-PD-L1 or anti-PD-L2
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent (only cohort A)
Prior treatment with PV-10 or any anti-PD-1 antibody
Subjects previously treated with any anti-PD-L1 antibody are eligible for study participation).
Patients that have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways are eligible, unless they discontinued such therapy due to toxicity
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor.
Participants who have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior therapy with any anti-PD-1, anti-PD-L1, L2, anti-4-1BB (CD137), or anti-CTLA 4 therapy.
Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Subject who has been treated with immunotherapy; this includes prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways
PHASE II EXCLUSION CRITERIA: Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents\r\n* Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met:\r\n** Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose\r\n** No history of severe immune-related adverse effects from anti-CTLA-4 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] grade 3 and 4)
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or IDO1 inhibitor or any other antibody or drug specifically targeting checkpoint pathways other than anti-CTLA-4 which is permitted in the adjuvant setting.
Subjects who have received prior anti-PD-1 or anti-PD-L1 antibody, or an IDO inhibitor; subjects who have received experimental vaccines or other immune therapies should be discussed with the principal investigator to confirm eligibility
Prior treatment with CD137 agonists or immune checkpoint-blockade therapies, including anti-CD40, anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies.
Prior treatment with any MEK inhibitor, an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
Prior treatment with T-cell co-stimulating or immune checkpoint blockade therapies, including anti?CTLA-4, anti?PD-1, and anti?PD-L1 therapeutic antibodies
Patients who have received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent are not eligible
Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint-blockade therapies, including anti-cluster of differentiation 40 (anti-CD40), anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4), anti-programmed death-1 (anti-PD-1), and anti-PD-L1 therapeutic antibodies
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways
Prior anti-cancer treatments such as chemotherapy, radiotherapy, hormonal, or immunotherapy (including anti-PD-1/PD-L1) are permitted
Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody
Prior disease progression on anti-PD-1 therapy
For Cohort Expansion, patients who have previously received an immune checkpoint inhibitor (e.g., anti-PD-L1, anti-PD-1, anti-CTLA-4) are not eligible for this study.
Prior therapy with an anti-PD-1, anti-PD-L1, anti-PDL-2, or anti-CTLA-4 antibody (or any other antibody targeting T cell co-regulatory pathways)
Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies, including anti-CD40, anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4), anti-programmed death-1 (anti-PD-1), and anti-PD-L1 therapeutic antibodies
Received prior therapy with an anti-CTLA-4, anti-PD-1, anti-PD1-ligand-1 (anti-PD-L1), or anti-PD-1 ligand-2 (anti-PD-L2) agent within 8 weeks prior to initiation of study treatment depending on study part
INCLUSION CRITERIA - For Parts 1-4:\n\n          -  Willing and able to provide written informed consent\n\n          -  Histologically confirmed diagnosis of a locally advanced (not amenable to curative\n             therapy such as surgical resection) or metastatic melanoma, RCC, NSCLC, urothelial\n             carcinoma, or TNBC\n\n          -  Male or female patients, age 18 years or older at the time of signing the informed\n             consent form (ICF)\n\n          -  Life expectancy > 12 weeks\n\n          -  Patients must not have received prior interleukin-2 (IL-2) therapy\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n\n          -  Measurable disease per RECIST 1.1\n\n          -  Demonstrated adequate organ function within 14 days of treatment initiation\n\n          -  Oxygen saturation ? 92% on room air.\n\n          -  Subjects must be recovered from the effects of any prior chemotherapy, immunotherapy,\n             other prior system anticancer therapy, radiotherapy, or surgery. Clinically\n             significant toxic effect(s) of the most recent prior chemotherapy must be resolved to\n             Grade 1 or less (except alopecia and sensory neuropathy).\n\n          -  Women of childbearing potential must agree to use highly effective methods of birth\n             control. All participants must agree to use double barrier contraception during study\n             participation for at least 6 months after the last dose of study drugs.\n\n          -  Patients with stable brain metastases may be enrolled if certain criteria are met.\n\n          -  Fresh and archival tumor tissue available\n\n          -  Additional criteria may apply.\n\n        INCLUSION CRITERIA - For Part 2:\n\n          -  MELANOMA:\n\n               -  Histologically confirmed stage III (unresectable) or stage IV melanoma, as per\n                  American Joint Committee on Cancer (AJCC) staging system\n\n               -  Ocular melanoma will be excluded\n\n          -  Melanoma Subpopulation A 1st-line (1L):\n\n               -  Have not received prior anti-cancer therapy for advanced or metastatic melanoma\n\n               -  Known BRAF status, or consent to testing, as per regionally acceptable V600\n                  mutational status testing\n\n          -  Melanoma Subpopulation B (2nd- and 3rd-line (2-3L), anti-PD-1 or anti-PD-L1 therapy\n             relapsed/refractory):\n\n               -  2-3L, patients must have confirmed radiographic disease progression no earlier\n                  than 4 weeks after initial disease progression but within 3 months from last dose\n                  of anti-PD-1 or anti PD-L1 containing regimen. Patients must consent to providing\n                  pre-study scans (if available) to confirm radiographic progression.\n\n               -  Patients may have received no more than 1 prior anti-angiogenic therapy or\n                  cytotoxic chemotherapy regimen.\n\n          -  RENAL CELL CARCINOMA (RCC):\n\n               -  Advanced (not amenable to curative surgery or radiation therapy) or metastatic\n                  (AJCC stage IV) RCC\n\n               -  Histologically confirmed RCC with a clear-cell component.\n\n          -  RCC Subpopulation A (1L):\n\n               -  1L, patients may have not received prior anti-cancer therapy for advanced or\n                  metastatic RCC.\n\n          -  RCC Subpopulation B (2-3L, anti-PD-1 or anti-PD-L1 relapsed/refractory):\n\n               -  2-3L, patients must have confirmed radiographic disease progression no earlier\n                  than 4 weeks after initial disease progression but within 3 months from last dose\n                  of anti-PD-1 or anti-PD-L1 containing regimen. Patients must consent to providing\n                  pre-study scans (if available) to confirm radiographic.\n\n               -  Patients may have received no more than 1 prior anti-angiogenic therapy or\n                  cytotoxic chemotherapy regimen.\n\n          -  NON-SMALL CELL LUNG CANCER (NSCLC):\n\n               -  Histologically confirmed or cytologically confirmed diagnosis of stage IV NSCLC\n\n                    -  Patients with nonsquamous NSCLC must lack epidermal growth factor receptor\n                       (EGFR)-sensitizing mutation and/or anaplastic lymphoma kinase (ALK)\n                       translocation\n\n          -  NSCLC Subpopulation A (1L):\n\n               -  1L, patients must not have received prior anti-cancer therapy for advanced or\n                  metastatic NSCLC. Patients must have known PD-L1 status as per validated\n                  immunohistochemistry testing. Up to 20 patients will be enrolled in each\n                  subgroup:\n\n                    -  PD-L1 negative (PD-L1 < 1%),\n\n                    -  PD-L1 positive (PD-L1 ? 50%),\n\n                    -  PD-L1 low/intermediate (PD-L1 ? 1% - < 50%).\n\n               -  For patients who do not have known PD-L1 status, testing must be done using an\n                  FDA-approved PD-L1 test.\n\n          -  NSCLC Subpopulation B (2L, I-O therapy naïve):\n\n               -  2L, patients must have experienced disease recurrence or progression during or\n                  after one prior platinum doublet-based chemotherapy regimen for advanced or\n                  metastatic disease. Patients who received platinum-containing adjuvant,\n                  neoadjuvant, or definitive chemoradiation therapy given for locally advanced\n                  disease and developed recurrent (local or metastatic) disease within 6 months of\n                  completing therapy are eligible. Patients must not have received any prior\n                  immune-oncology regimens, including but not limited to checkpoint inhibitors such\n                  as anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any\n                  other antibody or drug specifically targeting T cell co-stimulation or checkpoint\n                  pathways, indoleamine 2,3 dioxygenase pathway inhibitors, cancer vaccines,\n                  adoptive cell therapies, or other cytokine therapies.\n\n          -  NSCLC Subpopulation C (2-3L, anti-PD-1 or anti-PD-L1 relapsed/refactory):\n\n               -  2-3L, patients must have confirmed radiographic disease progression no earlier\n                  than 4 weeks after initial disease progression but within 3 months from last dose\n                  of anti-PD-1 or anti-PD-L1 containing regimen. Patients must consent to providing\n                  pre-study scans (if available) to confirm radiographic.\n\n          -  UROTHELIAL CARCINOMA (UC)\n\n               -  Histologically or cytologically documented locally advanced or transitional cell\n                  carcinoma of the urothelium including renal pelvis, ureters, urinary bladder, or\n                  urethra. Patients with mixed histologies are required to have a dominant\n                  transitional cell pattern.\n\n               -  For patients who received prior adjuvant/neoadjuvant chemotherapy or\n                  chemo-radiation for urothelial carcinoma, a treatment-free interval of more than\n                  12 months between the last treatment administration and the date of recurrence is\n                  required to be considered treatment naive in the metastatic setting.\n\n          -  UC Subpopulation A (1L)\n\n               -  Enrollment of urothelial carcinoma 1L patients will target accrual of up to 20\n                  patients who are cis-ineligible and up to 20 patients, who after consultation\n                  with the Investigator, choose to forego front-line chemotherapy\n\n               -  Treatment naive and cisplatin-eligible patients who refuse standard of care.\n\n          -  UC Subpopulation B (1L) cisplatin-ineligible\n\n               -  Treatment naive and cisplatin-ineligible patients who meet at least one of the\n                  following criteria:\n\n                    -  Creatinine clearance (calculated or measured) < 60 mL/min\n\n                    -  Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade ? 2\n                       audiometric hearing loss\n\n                    -  CTCAE v4.03 Grade ? 2 peripheral neuropathy\n\n                    -  New York Heart Association (NYHA) Class III heart failure\n\n               -  No prior chemotherapy for inoperable locally advanced or metastatic urothelial\n                  carcinoma. Prior local intravesical chemotherapy is allowed if completed at least\n                  4 weeks prior to the initiation of study treatment.\n\n               -  Patients must not have received any prior immune-oncology regimens, including but\n                  not limited to checkpoint inhibitors such as anti-PD-1, anti-PD-L1, anti-PD-L2,\n                  anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically\n                  targeting T cell co-stimulation or checkpoint pathways, indoleamine\n                  2,3-dioxygenase pathway inhibitors, cancer vaccines, adoptive cell therapies, or\n                  other cytokine therapies.\n\n          -  UC Subpopulation C (3L, anti-PD-1 or anti-PD-L1 relapse/refractory)\n\n               -  Patients must have progressed on only one prior line of therapy that contains\n                  platinum-based chemotherapy in the metastatic setting or post platinum-based\n                  chemotherapy in an adjuvant setting with progression < 6 months.\n\n               -  Patients must have received only one prior line of therapy with an anti-PD-1 or\n                  anti-PD-L1 containing regimen, which must be their most recent anti-cancer\n                  treatment.\n\n               -  Patients must have confirmed radiographic disease progression no earlier than 4\n                  weeks after initial disease progression but within 3 months from last dose of\n                  anti-PD-1 or anti-PD-L1 containing regimen. Patients must consent to providing\n                  pre-study scans (if available) to confirm radiographic.\n\n          -  TRIPLE-NEGATIVE BREAST CANCER (1-2L, I-O therapy naïve)\n\n               -  Less than 1% of tumor cell nuclei test positive for estrogen and progesterone\n                  receptors determined by using standard immunohistochemistry (IHC)\n\n               -  Human epidermal growth factor 2 (HER2) negative as determined by local\n                  pathologist, using IHC or in situ hybridization\n\n               -  Patients may have received only 1 prior line of therapy with chemotherapy,\n                  adjuvant setting excluded, or patient refuses standard of care.\n\n               -  Must not have received any prior immune-oncology regimens, including but not\n                  limited to checkpoint inhibitors such as anti-PD-1, anti-PD-L1, anti-PD-L2,\n                  anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically\n                  targeting T cell co-stimulation or checkpoint pathways, indoleamine 2,\n                  3-dioxygenase pathway inhibitors, cancer vaccines, adoptive cell therapies, or\n                  other cytokine therapies.\n\n        INCLUSION CRITERIA - For Parts 3 and 4:\n\n          -  RENAL CELL CARCINOMA (1L):\n\n               -  Advanced (not amenable to curative surgery or radiation therapy) or metastatic\n                  (AJCC stage IV) RCC.\n\n               -  Histologically confirmed RCC with a clear-cell component.\n\n               -  Patients must not have received prior anti-cancer therapy for advanced or\n                  metastatic RCC\n\n          -  NON-SMALL CELL LUNG CANCER (1L):\n\n               -  Histologically confirmed or cytologically confirmed diagnosis of stage IV NSCLC\n\n               -  Patients with nonsquamous NSCLC must lack epidermal growth factor receptor\n                  (EGFR)-sensitizing mutation and/or anaplastic lymphoma kinase (ALK)\n                  translocation.\n\n               -  Patients must not have received prior anti-cancer therapy for advanced or\n                  metastatic NSCLC.\n\n        EXCLUSION CRITERIA - For Parts 1-4:\n\n          -  Use of an investigational agent or an investigational device within 28 days before\n             administration of first dose of NKTR--214\n\n          -  Females who are pregnant or breastfeeding\n\n          -  Participants who have an active autoimmune disease requiring systemic treatment within\n             the past 3 months or have a documented history of clinically severe autoimmune disease\n             that requires systemic steroids or immunosuppressive agents\n\n          -  History of organ transplant that requires use of immune suppressive agents\n\n          -  History of allergy or hypersensitivity to study drug components\n\n          -  Active malignancy not related to the current diagnosed malignancy\n\n          -  Evidence of clinically significant interstitial lung disease or active, noninfectious\n             pneumonitis\n\n          -  Prior surgery or radiotherapy within 14 days of therapy\n\n          -  Participants who have had < 28 days since the last chemotherapy, biological therapy,\n             or < 14 days from approved tyrosine kinase inhibitor (TKI) therapy (sunitinib,\n             sorafenib, vemurafenib, dabrafenib, cobimetinib, erlotinib, gefitinib, afatinib,\n             osimertinib), or systemic or inhaled steroid therapy at doses greater than 10mg of\n             prednisone or equivalent before administration of the first dose of study medication\n\n          -  Participant's inability to adhere to or tolerate protocol or study procedures\n\n          -  Additional criteria may apply.
Previously participated in any other pembrolizumab (MK-3475) study, or received prior therapy with an anti-programmed cell death (PD)-1, anti-PD-Ligand 1 (anti-PD-L1), anti-PD-L2, or any other immunomodulating mAb or drug specifically targeting T-cell co-stimulation or checkpoint pathways
The participant has received prior pembrolizumab or any other anti-PD-1, anti-PD-L1, or anti-PD-L2 therapy, or has participated in any prior studies involving pembrolizumab
Prior treatment with any anti-PD-1 blocking therapies or histone deacetylase inhibitors (HDACi), or anti-CTLA-4 antibody, CD137 agonist or other immune activating therapy such as anti-CD 40 antibody within the last 3 months of enrollment in the study
Prior treatment with anti?PD-1, or anti?PD-L1 therapeutic antibody or pathway-targeting agents
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways)
Prior receipt of survivin based vaccines or immune checkpoint inhibitors (e.g. anti-CTLA-4, anti-PD-1, anti-PD-L1, or any other antibody or drug specifically targeting T cell co-stimulation) or an IDO inhibitor
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent\r\n* This criterion does not apply to eligibility for second course treatment
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Previous therapy with histone deacetylase (HDAC) inhibitor and/or anti PD 1, anti PD L1, or anti CTLA4 immunotherapy.
Prior anti-human antibody response (anti-heart antibodies [AHA] or anti-drug antibody [ADA])
Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti CTLA-4, anti-PD1 and anti-PD-L1 therapeutic antibodies
Patients who have received previous therapy with an anti-CTLA4, anti-CD137, anti-PD-L1 or anti-PD-1 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
EXCLUSION CRITERIA FOR STRATUM C: Patients who have received previous therapy with an anti-CTLA4, anti-CD137, anti-PD-L1 or anti-PD-1 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Last dose of prior immunotherapies including but not limited to: interferon alpha, interferon-beta, interleukin (IL)-2, conjugated IL-2, cergutuzumab amunaleukin (CEA-IL2v) , cytokines, anti-cytotoxic T lymphocyte antigen-4, anti-PD-L1, or anti-PD-1 <28 days prior to first cergutuzumab amunaleukin infusion
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-cluster of differentiation (CD)137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) for metastatic breast cancer-or- if patient has had prior immune-oncology therapies in the neoadjuvant or adjuvant setting within the past 12 months.
Prior therapy with anti-PD-L1 and anti-PD1 antibodies, MEK inhibitors or MDM2 antagonists.
Prior therapy for melanoma with the following exceptions which are allowed: 1) surgery for the melanoma lesion(s), 2) adjuvant RT after neurosurgical resection for CNS lesions, and 3) prior adjuvant IFN (see qualifier below); specifically, patients who received prior therapy with anti-PD-1, anti-PD-L1, anti-programmed death ligand-2 (PD-L2), anti-clusters of differentiation (CD)137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways) are not eligible\r\n* Prior treatment with adjuvant IFN is allowed if completed >= 3 months prior to treatment, and adjuvant ipilimumab if >= 6 months prior to treatment
Patients must not have had prior immunotherapy with anti-PD-L1, anti-PD-1, anti-CTLA4 or similar drugs.
Have received an anti-PD1 or anti PDL1 monoclonal antibody
Prior immunotherapy including anti-PD-1, anti-PD-L1, or anti-PD-L2 agents
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137)
Prior immunotherapy including but not limited to anti-CTLA4, including tremelimumab anti-PD-1, and anti-PD-L1, including durvalumab.
Previous systemic exposure to anti-CTLA-4 antibody or anti-PD1 antibody
Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or anti CTLA-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Prior therapy with any antibody / drug targeting T cell coregulatory proteins (immune checkpoints) such as anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Participants may have had prior immuno-oncology (IO) therapy (including but not limited to anti-CTLA4 and anti-PD1/L1) excluding prior CSF1R directed agents for the study arm containing cabiralizumab
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Patients must have prior exposure to an anti-PD1 or anti-PDL1 mAb, if eligible for immunotherapy in the judgment of the local investigator
Prior exposure to investigational immunotherapies, including anti-CTLA4, anti-OX40, anti-CD40, anti-CD27, anti-TNFR antibodies or other investigational immunotherapies, is acceptable
For Parts B and C, patients who received previous anti- PD-1, anti-PD-(L)1 treatment
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Patients may not have received prior anti PD-1 or anti PD-L1 inhibitors
History of prior therapy with an IDO1 inhibitor in combination with an anti-PD-1/anti-PD-L1 agent/any other drug specifically targeting checkpoint pathways; patients who have received prior therapy with single agent anti-PD-1/anti-PD-L1 therapy or single agent IDO1 inhibitor will be eligible for this study
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-CTLA-4, anti-PD-1, anti-PD-L1, or anti-PDL2 agent
Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) is not permitted
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (TCR) (e.g., CTLA-4, OX 40, CD137).
MEDICATION-RELATED: Prior history of treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA4 or any other antibodies targeting co-stimulation or checkpoint pathways.
Immune-checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1, or anti-CTLA-4), monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or T-cell or other cell-based therapies: 4 weeks (2 weeks with documented disease progression).
No prior treatment with anti PD1, anti PD L1, anti CTLA 4 antibody or any other antibody or drugs targeting T cell costimulation or checkpoint pathways, or cetuximab or EGFR inhibitors in any treatment setting.
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Prior treatment with anti-PD1 or anti-PD-L1 antibody therapy
Prior treatment with CD137 agonists, anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway targeting agents
Patients who have experienced grade 3 or above toxicity from prior anti-PD1 therapy
Any prior therapy with anti-PD-1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
ARM I INCLUSION CRITERIA: Subjects are currently on checkpoint inhibitor (anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody, or antibodies to tumor necrosis factor family including OX40) or tumor vaccine for systemic disease who develop new brain metastases, must have documented stable systemic disease within 30 days of signing consent
ARM I INCLUSION CRITERIA: Subjects who have completed prior checkpoint inhibitor (anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody, or antibodies to tumor necrosis factor family including OX40) or tumor vaccine for systemic disease but are now off therapy with documented stable systemic disease within 30 days of signing consent may be enrolled after discussion with the Merck & Co clinical team
Prior therapy with an anti-PD-1, anti PD-L1, anti-PD-L2, anti-CD137 antibody, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) agents
Any prior therapy with anti-PD-1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Prior therapy with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway targeting agents.\r\n* Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met:\r\n** Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose.\r\n** No history of severe immune-related adverse effects from anti-CTLA-4 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] grade 3 and 4).
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-CTLA4 or anti-PD-L2 agent
Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T cell costimulation or checkpoint pathways)
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including pembrolizumab, ipilimumab, and any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Prior or concurrent immunotherapy, including treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody; tumor vaccines; interferon, or interleukins.
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
Prior treatment with anti-PD-1, CTLA-4, or anti-PD-L1 therapeutic antibody or pathway-targeting agents
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
No prior treatment with cancer immunotherapy including, but not limited to, other anti-CTLA-4, anti-PD-1, anti-PD-L1, and anti-programmed cell death ligand 2 anti- (PD-L2) antibodies, excluding therapeutic anticancer vaccines
Patients can be either naive for any previous systemic treatment or have had any number of prior systemic therapies. However, patients must not have received prior anticancer therapy with anti-PD1, anti-PD-L1, or anti-CTLA-4 immune checkpoint inhibitors.
Patients must not have received prior anticancer therapy with anti-PD1, anti-PD-L1, or anti- CTLA-4 immune checkpoint inhibitors.
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Previous anti-PD1 or anti-PD-L1
Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or anti CTLA-4 antibody
Current or prior anti-cancer treatment prior to the first dose of pembrolizumab as defined below:\r\n* Chemotherapy, targeted small molecule therapy, or other anti-cancer treatment not otherwise specified below within 2 weeks\r\n* Radiation therapy within 2 weeks\r\n* Anti-cancer monoclonal antibody (mAb) treatment within 4 weeks\r\n* Use of an investigational agent (e.g., biologic, drug, or other) within 4 weeks\r\n* Allogeneic stem cell transplant within 100 days\r\n* Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent at any time
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent within the prior 24 weeks
Prior anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) is allowed in part 1 (phase 1b) and is required for phase 2 cohort B of the study
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) for the immunotherapy-naive cohort only
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 agent, or mifepristone
Has prior exposure to anti-PD1/PD-L1 or anti-CTLA4 therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Prior treatment with anti-PD-1/PD-L1, and anti-CTLA-4 is NOT allowed; prior intravesical Bacillus Calmette–Guérin (BCG) therapy is allowed
No prior exposure to immune-mediated therapy including, but not limited to, other anti CTLA-4, anti-PD-1, anti-PD-L1, and anti-programmed cell death ligand 2 (anti-PD-L2) antibodies, including therapeutic anticancer vaccines; the exception to this is those whose tumors are microsatellite instable-high (MSI-hi) and are refractory to anti-PD1 monotherapy
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway targeting agents; but patients who have received prior treatment with anti·CTLA-4 may be enrolled, provided the following requirements are met: (1) minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose; (2) no history of severe immune-related adverse effects from anti-CTLA 4 (National Cancer Institute [NCI] Common Terminology for Cancer Adverse Effects CTCAE] grade 3 and 4)
Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has been receiving anti-PD-1 or anti-PD-L1 immunotherapy for at least four weeks
(Atezolizumab-related exclusion) Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway targeting agents a) Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met: Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose. No history of severe immune-related adverse effects from anti-CTLA 4 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] Grade 3 and 4)
Prior checkpoint inhibitor therapy including anti-PD1, anti-PD-L1, anti-CTLA4, anti- CD137, or anti-PD-L2 therapy
Prior treatment with an anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibody
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Patients who received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent without having had evidence of objective response
Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti?CTLA-4, anti?PD-1, and anti?PD-L1 therapeutic antibodies\r\n* Prior cancer vaccines and cellular immunotherapy are permitted
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Any prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1, including anti-PD-1, anti-PD-L1, anti-CD137, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways, except for endocrinopathies and asymptomatic amylase/lipase
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Patients with prior therapy with antibodies that modulate T-cell function (e.g., anti-PD-1, anti-PD-L1)
Any previous treatment with an anti-PD-1, anti-PD-L1 or anti-CTLA-4 therapy, including durvalumab and tremelimumab
Patients who have had prior treatment with an anti-PD1, anti-PDL1, anti-PDL2, anti-CTLA4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways are not eligible
Exclusion criteria related to study medication (any cancer immunotherapy including CD137 agonists, anti-PD-1, anti-PD-L1, or anti-CTLA4 or any MEK or ERK inhibitor)
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) antibody, anti-CD137, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Colorectal patients are excluded if they have had prior systemic treatment with an anti-CTLA4, anti-PD1 or PDL1 antibody; pancreatic patients are excluded if they have previously received anti-CTLA-4 therapy; prior PD-1 or PDL1 therapy will be permitted for pancreas patients
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Prior treatment with an anti-CD137, or OX40 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways except anti-PD1, anti-PDL1/2 antibodies or ipilimumab
Progression while on prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2, anti-tumor necrosis factor CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent; anti-CD137 or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways; prior treatment with HD IL-2 is allowed
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Patients may not have had prior therapy with a checkpoint inhibitor (e.g. anti-CTLA-4, anti-PD-1 or anti-PD-L1 therapy)
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
* Patients should be excluded if they have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway targeting agents\r\n* Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met:\r\n** Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose\r\n** No history of severe immune-related adverse effects from anti-CTLA 4 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] grade 3 and 4)
Prior immunotherapy or treatment with another anti PD 1 agent
Previous or current treatment with an anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4), anti-programmed death (PD)-1, anti-PD ligand (PD-L)1, or anti-PD-L2 agent
Patients should be excluded if they have had prior treatment with anti-CTLA-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation; previous treatment with anti-PD-1, anti-PD-L1 or anti-PD-L2 is allowed and patients will be enrolled in the exploratory cohort (arm C) at the time of progression from last line of treatment (treatment with immune check point inhibitor does not have to necessary be the last line of treatment)
Prior history of receiving immune modulators including, but not limited to, anti-CTLA4, anti-PD1, anti-PD-L1
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Tumor progression or recurrence during or after treatment with anti-PD1, anti-PDL1, anti-PDL2, anti-CTLA4, or other immune checkpoint inhibitor where the most recent dose was given within 3 months prior to study registration
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti- Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Patients must not have received prior anticancer therapy with any immune checkpoint inhibitors such as anti-CLTA-4, anti-PD1, or anti-PD-L1
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Prior therapy with antibody or drug specifically targeting T cell regulatory proteins, including but not limited to: prior immunotherapy with IL-2 or IFN-alpha, or an anti-PD-1 (including nivolumab), anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) antibody (including ipilimumab), or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PDL-2 antibody
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Prior therapy with an anti-PD-1/PD-L1 antibody or a TRAIL-DR5 antibody
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Previous therapy for this cancer with an anti-PD-1, anti-PD-L1, anti-PD-L2 agent, or any other immunomodulatory agent
Has received prior anti-PD-1 or anti-PD-L1 therapy
patients who have received all therapy known to confer clinical benefit (including anti-PD-1 or anti-PDL1 therapies, if relevant), or for whom no therapy of proven efficacy exists, or who are not amenable to standard therapies. Patients with anti- PD-1 or anti-PDL1 experience must have a minimum of 60 days between the last dose of the previous anti PD-1/PD-L1 and Cycle 1 Day 1 of BI 754091 treatment.
patients who are anti-PD-1 and anti-PDL-1naïve but have failed conventional treatment (excluding anti-PD-1 treatment), or for whom no therapy of proven efficacy exists, or who are not amenable to standard therapies.
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior immunotherapy including anti-PD-1, anti-PD-L1, or anti-PD-L2 agents, or if the subject has previously participated in Merck pembrolizumab clinical trials
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
No prior immune checkpoint inhibitors (e.g., anti-CTLA4, anti-PD-1 or anti-PDL1 are allowed
Patients with ongoing toxicities related to prior therapies targeting T cell coregulatory proteins (immune checkpoints) such as anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody are excluded
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Patients who have had prior exposure to immune checkpoint inhibitors are not eligible; please contact principal investigator, William Gradishar at 312-695-4541 for specific questions on potential interactions\r\n* PD-1 monoclonal antibody: pembrolizumab, pidilizumab, MEDI-0680, anti-PD-1 fusion protein AMP-224 (AMP-224), anti-PD-1 checkpoint inhibitor PF-06801591 (PF-06801591), anti-PD-1 monoclonal antibody BGB-A317 (BGB-A317), anti-PD-1 monoclonal antibody PDR001 (PDR001), anti-PD-1 monoclonal antibody REGN2810 (REGN2810), anti-PD-1 monoclonal antibody SHR-1210 (SHR-1210)\r\n* PD-L1 monoclonal antibody: durvalumab, avelumab, anti-PD-L1 monoclonal antibody MDX-1105 (MDX-1105), atezolizumab, zirconium Zr 89-labeled anti-PD-L1 monoclonal antibody MPDL3280A (MPDL3280A)\r\n* CTLA4 monoclonal antibody: tremelimumab, abatacept\r\n* OX40: agonistic anti-OX40 monoclonal antibody MEDI6383 (MEDI6383), agonistic anti-OX40 monoclonal antibody MEDI6469 (MEDI6469), anti-OX40 monoclonal antibody MEDI0562 (MEDI0562), oxelumab, anti-OX40 antibody PF-04518600 (PF-04518600)
Has received prior therapy with an anti-programed death receptor 1 (PD-1), anti-PD-L1, anti-program death receptor ligand 2 (PD-L2) agent or anti-CTLA4
Prior exposure to any anti-PD-1 or anti-PD-L1 antibody, or any anti-cytotoxic T-lymphocyte-associated protein (CTLA) 4 antibodies
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2 agent
Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4 antibody therapies, any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Patients who have received prior therapy with immune checkpoint inhibitors (e.g. anti-PD-1, anti-PD-L1, anti-LAG3, anti-CTLA-4) or immune costimulatory molecules (e.g. anti-CD137, anti-OX40, anti-GITR) directed agents
Anti-PD-1, anti-PD-L1, or anti-PD-L2 agents
Has received prior therapy with an anti-PD-1, anti-PD-L-1, or anti-PD-L2 agent
Prior therapy with anti-PD1, anti-PD-L1 or anti-cytotoxic T-lymphocyte protein (CTLA)-4 antibody
Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody (or any other antibody targeting T cell co-stimulation pathways)
Subjects must have no prior exposure to immunotherapy, such as, but not limited to other anti-CTLA-4, anti-PD-1, or anti-PD-L1 antibodies excluding vaccines
Patients who received prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) are not eligible
Has received prior therapy with an anti-PD-1, PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior treatment with any anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or sEsphB4-HSA
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Has received prior therapy with an PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte associated antigen-4 antibody (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior treatment with an anti-PD-1, anti-PD-L1 or anti-PD-L2 agent
Prior treatment with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Prior therapy with anti-PD1 antibody
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
Prior exposure to immune-mediated therapy, including but not limited to, other anti cytotoxic T-lymphocyte-associated protein 4 (CTLA 4), anti-PD-1, anti-PD-L1, or anti-PD-L2 antibodies, including therapeutic anticancer vaccines. Prior local intervesical chemotherapy or immunotherapy is allowed if completed at least 28 days prior to the initiation of study treatment.
Prior immunotherapy with IL-2, IFN-?, or anti PD 1, anti PD L1, anti PD L2, anti CD137, or anti cytotoxic T lymphocyte associated antigen 4 (CTLA 4) antibody (including ipilimumab), or any other antibody or drug specifically targeting T cell co stimulation or immune checkpoint pathways
For Dose escalation: subjects with cervical, ovarian, bladder and colorectal cancer (CRC), head and neck, gastric and hepatocellular cancer naive to immuno-oncology agents; 1st line melanoma and 1st line/2nd line NSCLC; Renal Cell Carcinoma naive to IO; NSCLC progressing while on or after therapy with anti-PD1/anti-PDL-1 and melanoma subjects progressed while-on or after treatment with anti-PD1 or anti-PDL1 with or without anti-CTLA-4.
Patients who have had prior therapy (BRAF inhibitors, ipilimumab, anti PD-1 antibody or anti PD-L1 antibody) or treatment naive patients are eligible as long as toxicity from therapy is grade =< 1 or at baseline
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2
Subject has received prior therapy with an anti-PD-1, anti-PD-ligand 1 (L1), anti-PD-L2, anti-cluster of differentiation (CD)137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) agents (including ipilimumab), interferon, high dose interleukin 1 (IL-1) or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Has received prior therapy with PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) within 3 months
Prior immunotherapy is allowed (previous immune checkpoint inhibitors; anti-CTLA-4, anti-PD-1, anti-PD-L1 and/or combinations), except for the patients enrolled to the immunotherapy naïve group of the phase IB dose expansion.
Prior treatment with a CD137 agonists, anti-CTLA4 (except melanoma), anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway targeting agents
Has received prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2, anti-cluster of differentiation (CD)137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-cluster of differentiation (CD)137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior therapy with an anti-PD-1, anti-PD-L1, anti-PDL-2, or anti-CTLA-4 antibody (or any other antibody targeting T cell co-regulatory pathways)
Patients with a history of prior treatment with anti-CTLA-4, anti-PD 1 antibody, or anti-PDL1 antibody
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has had prior treatment with an anti-PD-1 or anti-PD-L1 antibody, anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab) or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways;
Prior exposure to immune-mediated therapy, including anti-PD-1, anti-PD-L1 (including durvalumab) or anti-CTLA-4 directed therapy (including tremelimumab); therapeutic anticancer vaccines are not included in this category; exposure to other investigational agents may be permitted after discussion with the study principal investigator (PI)
Prior exposure to immunotherapy including, but not limited to, anti-PD1 or anti-PDL1 antibodies is allowed but not required.
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Prior treatment with an anti-programmed death-1 (PD-1), anti-PD-L1, anti PD L2, anti-CD137, or anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co stimulation or checkpoint pathways.
Patients who have received prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody, or pathway -targeting agents\r\n* Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met:\r\n** Minimum of 12 weeks from the first dose of anti-CTLA-4 and >6 weeks from the last dose\r\n** No history of severe immune-related adverse effects from anti-CTLA-4 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] grade 3 and 4)
Patients should be excluded if they have had prior treatment with a Pi3 kinase inhibitor, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Prior treatment with CD137 agonists or immune checkpoint-blockade therapies, including anti-CD40, anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies
ORAL CAVITY SQUAMOUS CELL CARCINOMA COHORT: Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
HPV-ASSOCIATED OROPHARYNX SQUAMOUS CELL CARCINOMA: Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T cell receptor
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or blinatumomab
Prior PD-1 or PD-L1 inhibitor therapy, or prior therapy with anti-PD-L2 or anti-CTLA-4 inhibitor, or any other drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
REGISTRATION TO TREATMENT (STEP 1): Patient must not have received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway targeting agents. Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met: Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose. No history of severe immune-related adverse effects from anti-CTLA 4 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] grade 3 and 4).
Prior exposure to anti-PD-1, anti-PD-L1, CCR2/5, or anti-CTLA4 antibodies
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents\r\n* Note:\r\n** Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met:\r\n*** Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose\r\n*** No history of severe immune-related adverse effects from anti-CTLA-4 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] grade 3 and 4)
Patients who have had prior exposure to immune-mediated therapy defined as prior exposure to T-cell and natural killer cell directed therapy (e.g. anti-PD-1, anti-PD-L1, anti-CD137, and anti-CTLA4, etc).
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent for dose expansion; (patients in dose escalation may have received an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent)
Any previous treatment with a hypomethylating agent, or with a PD1 or PD-L1 or anti-PD-L2 or anti-CTLA4 inhibitor, including durvalumab (or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways); any immunomodulatory agent that is not described above should be cleared by the principal investigator (PI)
Patients that who have relapsed after at least 1 prior anti-lymphoma therapy that include anti-CD20 monoclonal antibody and an alkylator chemotherapy agent, or at least 2 prior anti-lymphoma therapies that include anti-CD20 monoclonal antibody, may be included.
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents\r\n* Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met:\r\n** Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose\r\n** No history of severe immune-related adverse effects from anti-CTLA-4 (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] grade 3 and 4)
Prior treatment with an anti-PD1, anti-PDL1, anti-PDL2, anti-CD137, or anti-CTLA4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or other immune checkpoint inhibitor (e.g. anti-CTLA4)
Have experienced disease progression during treatment with an anti-PD1/L1 antibody as the treatment regimen immediately prior to accrual to this study or disease progression within 6 months of adjuvant anti-PD1 antibody
Prior treatment with immune checkpoint blockade therapies (anti-cytotoxic T-lymphocyte-associated protein 4 [anti-CTLA-4], anti-programmed death-1 [anti-PD-1] or anti-PD-L1) or immune agonists (anti-cluster of differentiation [CD]137, anti-CD40, anti-OX40)
Prior treatment with an investigational compound being tested in this study (e.g., poly ADP ribose polymerase [PARP] inhibitor, anti-PD-1, anti-PD-L1, or anti-PD-L2)
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents\r\n* Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met:\r\n** Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose\r\n** No history of severe immune-related adverse effects from anti-CTLA-4 (NCI CTCAE grade 3 and 4)
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T cell co-stimulation or checkpoint pathways)
Patients who have had prior treatment with anti-PD1 or anti-CTLA4 therapy
Prior treatment with immune checkpoint blockade therapies (anti-cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], anti-programmed death-1 [PD-1] or anti-PD-L1) or immune agonists (anti-cluster of differentiation [CD] 137, anti-CD40, anti-OX40)
Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti- cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways)
Any prior therapy with anti-PD-1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-programmed death-ligand 2 (PD-L2), anti-cluster of differentiation (CD)137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Patients are excluded if they have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-ligand 2 (L2), anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137)
Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Prior treatment with anti?PD-1, or anti?PD-L1 therapeutic antibody or pathway targeting agents
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Patients who have had prior therapy with nivolumab or with an anti-PD-1, anti-PD-ligand (L)1, anti-PD-L2, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune check point pathways
Patients who have had a grade one or grade two gastrointestinal adverse event during or after receiving anti-CTLA-4, anti-PD1 or anti-PD, without a colonoscopy verifying complete resolution of the adverse event
Study participants who had prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Study participants with known immune impairment who may be unable to respond to anti-cytotoxic T-lymphocyte antigen 4 (CTLA 4) antibody and/or anti-PD-1 antibody
Prior treatment with interferon (if complete < 6 months prior to participation in study), anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Patients must not have had prior treatment with an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2, anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways
Prior treatment with an anti-Programmed Death (PD) -1, anti-PD-L1, anti-PD-L2, anti-cluster of differentiation 137 (CD137), or anti-cytotoxic T-lymphocyte-associated antigen 4(CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways. This includes the utilization of these agents in the neo-adjuvant or adjuvant setting.
Immune-checkpoint inhibitors (i.e., anti-PD-1, anti-PD-L1, or anti-CTLA-4): 4 weeks
Prior treatment with an anti-Programmed Death Receptor (PD)-1, anti-PD-L1, anti-PD-L2, anti-Cytotoxic T-Cell Lymphoma-4 Antigen (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Has received prior immunotherapy including anti-programmed cell death-1 (anti-PD-1), anti-PD-ligand-1 (anti-PD-L1), or anti-PD-L2 agents, or if the participant has previously participated in Merck pembrolizumab (MK-3475) studies.
Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 antibody.
Has previously participated in any other pembrolizumab (MK-3475) trial, or received prior therapy with an anti-programmed cell death 1 (anti-PD-1), anti-PD ligand 1 [anti-PD-L1], and anti-PD-L2
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or if the patient has previously participated in MK-3475 clinical trials.
Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, or anti-PD-L2 agent
Melanoma immune checkpoint-naïve: Subjects must not have received immunotherapy with anti-PD-1, anti-PD-L1, or anti-CTLA-4 therapy. Exception: Prior anti?CTLA-4 in the adjuvant setting would be permitted.
Subjects must not have received prior immunotherapy with anti-PD-1, anti-PD-L1, or anti-CTLA-4 therapy.
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways). Exception: Prior anti?CTLA-4 in the adjuvant setting for subjects with melanoma would be permitted.
Prior therapy with an antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways, including, but not limited to, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T lymphocyte associated antigen 4 (anti-CTLA-4) antibody.
Has received prior therapy with an anti-PD-1, or anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], OX-40, CD137).
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or IDO1 inhibitor or any other antibody or drug specifically targeting checkpoint pathways other than anti-CTLA-4 which is permitted in the adjuvant setting
Prior systemic anti-cancer treatment for EOC, FTC, or PPC including prior immunotherapy with IL 2, IFN ?, or anti PD 1, anti PD L1, anti PD L2, anti CD137, or anti cytotoxic T lymphocyte associated antigen 4 (anti CTLA 4) antibody (including ipilimumab), or any other antibody or drug specifically targeting T cell co stimulation or immune checkpoint pathways
Prior treatment with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti PD-1, and anti PD-L1 therapeutic antibodies, or any other antibody or drug targeting T-cell costimulation.
GVHD therapies: Any systemic drug used for GVHD must be stopped > 4 weeks prior to CTL019 infusion to confirm that GVHD recurrence is not observed (e.g. calcineurin inhibitors, methotrexate or other chemotherapy drugs, mycophenolate, rapamycin, thalidomide, or immunosuppressive antibodies such as anti-CD20 (rituximab), anti-tumor necrosis factor [anti-TNF], anti-interleukin 6 [anti-IL6] or anti-interleukin 6 receptor [anti-IL6R], systemic steroids)
Prior therapy with experimental anti-tumor vaccines; any T cell co-stimulation or checkpoint pathways, such as anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, including Ipilimumab; or other medicines specifically targeting T cell is also prohibited
PRIOR/CONCURRENT THERAPY CRITERIA: Prior treatment with an anti-PD-1 or anti-PDL1 is not required
Prior therapy with an anti PD 1, anti PD L1, anti PD L2, anti CD137, or anti cytotoxic T lymphocyte associated antigen 4 (CTLA 4) antibody (including ipilimumab, tremelimumab or any other antibody or drug specifically targeting T cell co stimulation or immune checkpoint pathways).
Subject has had prior therapy with T-cell immune modulating antibodies, including anti-CTLA-4, anti-PD-1 or anti-PD-L1.
No prior treatment with anti-PD-1 or anti-PD-L1
Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including pembrolizumab, ipilimumab, and any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Subject has been previously treated with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways;
Subject had prior exposure to immunotherapy, including, but not limited to, other anti- CTLA-4,anti-PD-1, anti-PD-L1 monoclonal antibody or inhibitor, cell-based therapies, or cancer vaccines
Received prior immune checkpoint inhibitors (e.g., anti-CTLA-4, anti-PD-1, anti PDL-1) and any other antibody or drug specifically targeting T-cell costimulation or an IDO inhibitor
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or if the patient has previously participated in Merck MK-3475 clinical trials.
Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA4, anti-PD-1, and anti-PD-L1 therapeutic antibodies
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or if the subject has previously participated in Merck MK-3475 clinical trials.
Prior systemic treatment with and anti-PD1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways
Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2 agent, or agents targeting other checkpoint pathways (e.g. CTLA-4)
Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies
Prior therapy with an anti-PD-1, anti-PD-L1, anti-PDL-2, or anti-CTLA-4 antibody (or any other antibody targeting T cell co-stimulation pathways)
Prior exposure to tremelimumab or durvalumab or other anti-CTLA-4, anti-PD-1, anti-PD-L1 antibodies
Has received prior immunotherapy including anti-programmed death-1 (anti-PD-1), anti-PD-ligand-1 (anti-PD-L1), or anti-PD-L2 agents, or if the participant has previously participated in clinical studies with pembrolizumab (MK-3475)
No prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody.
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or if the patient has previously participated in a Merck MK-3475 clinical trial.
Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2, anti-tumor necrosis factor CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways), or took part in another pembrolizumab trial
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway targeting agents
Prior treatment with anti-PD-1, and CTLA-4, or anti-PD-L1 therapeutic antibody or pathway-targeting agents
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Prior treatment with an anti PD-1, anti PD-L1, or anti CTLA-4 agent; participants who entered clinical remission with one of those agents and proceeded to ASCT without intervening relapse may be eligible after discussion with the study chair; note that for patients who enter remission with checkpoint blockade therapy, this will not count towards the 3 lines of prior therapy
Prior immunotherapies including but not limited to CD137, anti-PD-1, anti-PD-L1, and CTLA4.
CD137 agonists, immune checkpoint inhibitors including but not limited to CTLA-4, anti-PD-1, and anti-PD-L1 therapies
Prior immune therapy for NSCLC excluded. Patients should be excluded if they have had prior treatment with an anti-PD-1, anti-PD-L1, anti PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways.
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents
Prior treatment with anti-PD-1, PD-L1, or CTLA4, or ensartinib (X-396).
Participants may not have received any prior treatment with an anti-PD-1, anti PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Patients who have had prior exposure to checkpoint blockade therapy, such as anti-PD-1/PD-L1, anti-cytotoxic T-lymphocyte associated protein 4 (CTLA4), anti-CD137, and anti-OX40 antibody therapy, are not eligible
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or has participated in another Merck pembrolizumab clinical trial
Has received prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior immunotherapy with IL-2, IFN-?, or anti PD 1, anti PD L1, anti PD L2, anti CD137, or anti cytotoxic T lymphocyte associated antigen 4 (CTLA 4) antibody (including ipilimumab), or any other antibody or drug specifically targeting T cell co stimulation or immune checkpoint pathways
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-cluster of differentiation (CD)137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior therapy with anti-PD-1, anti-PDL1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, OR other immune check point agonist/inhibitor.
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 monoclonal antibody.
Prior exposure to doxorubicin, PLD or any other anthracycline, motolimod and other TLR agonists, MEDI4736 or checkpoint inhibitors, such as anti-CTLA4 and anti-PD1/anti-PD-L1 antibodies.
Received prior therapies: ibrutinib, or other BTK inhibitor and/or anti-PD1, anti-PD-L1, anti-PD-L2, anti-CD137, or CTLA-4 antibody
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior treatment with an anti-PD-1,anti-PD-L1,anti-PD-L2,anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, anti-CD137 or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways Exclusion laboratory criteria:
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
Prior immunotherapy including anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or previously participated in Merck pembrolizumab (MK-3475) clinical trial
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-cluster of differentiation (CD)137; patients who received anti-cytotoxic T-lymphocyte antigen 4 (CTLA4) (ipilimumab, tremelimumab) will NOT be excluded and are eligible for inclusion
Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or previously participated in Merck MK-3475 clinical trial
Prior exposure to any anti-PD-1 or anti-PD-L1 antibody or anti CTLA4
Received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Has received prior therapy with an anti-programmed cell death (PD)-1, anti-PD ligand (PD-L)1, anti-PD-L2, anti-cluster of differentiation (CD)137 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Has received prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2, anti-cluster of differentiation (CD)137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another co-inhibitory T-cell receptor
Prior BTK inhibitor or anti PD1, anti PDL1, anti PD-L2 and anti-CD137, anti-cytotoxic T-lymphocyte associated antigen (CTLA-4) antibody
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-cluster of differentiation (CD)137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-cluster of differentiation (CD)137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or other antibody or drug specifically targeting T-cell co-stimulation)
Has received prior therapy with an anti-programmed cell death protein 1 (PD-1), anti-PD-L1, anti-PD-L2, anti-cluster of differentiation 137 (CD137), or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior therapy with an anti-PD-1 or anti-PD1-L1 or -L2 therapy or previously participated in a Merck pembrolizumab (MK-3475) trial
Patients with a history of prior treatment with anti-PD-1, anti-PD-ligand (L)1, anti-PD-L2, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) antibodies, or who have received both GVAX or CRS-207 will be excluded
Prior treatment with an anti-programmed death (PD)-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Prior exposure to any anti-PD-1 or anti-PD-L1 antibody.
Prior exposure to any anti-PD-1 or anti-PD-L1 antibody
Has previously participated in any other pembrolizumab (MK-3475) trial, or received prior therapy with an anti-PD-1, anti-PD-L1, and anti-PD-L2 (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior treatment with CD137 agonists, anti-CTLA4, anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents
Prior exposure to tremelimumab or MEDI4736 or other anti-CTLA-4, anti-PD-1, anti-PDL1 antibodies
Ocular melanoma; and have received no more than one line of systemic therapy for metastatic disease. Patients must not have received immune modifying agents (eg. anti PD-L1, anti PD-1, anti CTLA4, TNF agonist, etc.) for metastatic disease, or
Cutaneous/acral melanoma; and have 1) only previously received systemic therapy for advanced/metastatic disease with the following therapies: BRAF and MEK inhibitors, anti PD-L1, anti PD-1, or anti-CTLA4 and 2) have received checkpoint inhibitor (anti PD-L1, anti PD-1, or anti-CTLA4) based treatment as most recent line of therapy on which disease progressed, as long as progression did not occur in the first 3 months of receiving checkpoint inhibitor treatment. Arm 2 only:
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents\r\n* Patients who have received prior treatment with anti-cytotoxic T lymphocyte-associated antigen (CTLA-4) may be enrolled, provided the following requirements are met:\r\n** Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last\r\ndose\r\n** No history of severe immune-related adverse effects from anti-CTLA-4 (National Cancer Institute [NCI] common terminology criteria for adverse events [CTCAE] grade 3 and 4)
Prior Therapies:\r\n* Treatment with a monoclonal antibody within 4 weeks prior to study day 1 or has not recovered (i.e., >= grade 1 at baseline) from adverse events due to agents administered > 4 weeks earlier\r\n* Prior chemotherapy, targeted small molecule therapy, within 3 weeks prior to study day 1 or has not recovered (i.e., >= grade 1 at baseline) from adverse events due to a previously administered agent (excluding grade 2 neuropathy)\r\n* Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior immunotherapy with IL-2, IFN-?, or an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, OX 40, GITR, LAG 3, IDO, TDO,TIM 3, CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways. Prior treatment with Sipuleucel-T for patients with mCRPC is allowed.
Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T cell co-stimulation or immune checkpoint pathways
Prior exposure to any anti-PD-1 or anti-PD-L1 antibody
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) for the immunotherapy-naive cohort only
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents or eribulin\r\n* Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met:\r\n** Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose\r\n** No history of severe immune-related adverse effects from anti-CTLA-4 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version 5.0)
Prior histone deacetylase (HDAC) inhibitor and/or anti-PD1, anti-PDL1, anti-PD-L2, anti-CD137 or anti-cytotoxic T- lymphocyte associated antigen 4 (CTLA-4) antibody allowed as long patient received clinical benefit from it, best response was not progressive disease and it was not the most recent treatment
Patients should be excluded if they have had prior systemic treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways
Expansion Cohort 8: Subjects with Stage IV non-squamous NSCLC who have not received prior immune checkpoint inhibitor therapy (anti-PD-1 or anti-PD-L1).
Prior treatment with cabozantinib or immune checkpoint inhibitors including anti-CTLA-4, anti-PD-1, anti-PD-L1, or anti-PD-L2 therapy except in Expansion Cohorts 5 and 7 in which prior anti-PD-1 or anti-PD-L1 therapy is required for eligibility. Other restrictions regarding prior therapy may apply.
Patients who received prior anti-PD-1 therapy are eligible for cohort 1 only and patients who have not received prior anti-PD-1 therapy are eligible for cohort 2 only
Prior therapy with any antibody/drug targeting T-cell co-regulatory proteins (immune checkpoints) such as anti-PD-1, anti-PD-L1, or anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibodies. For subjects with metastatic melanoma, prior treatment with CTLA-4-blocking antibody is permissible.
Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
With TNBC has received prior therapy with an anti-PD-1, anti-PD-L1, anti-CTLA-4, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Tumor for which standard therapy, including approved anti-PD-1 or anti-PD-L1 therapy, when applicable, does not exist or is no longer effective.
Prior treatment with immune checkpoint inhibitors (eg, anti-CTLA-4, anti-PD-1, anti-PD-L1, and any other antibody or drug specifically targeting T-cell co-stimulation) or an IDO inhibitor.
Previous treatment with anti-PD-1, anti-PD-L1 or anti-PD-L2 therapy.
Participants in the Monotherapy Expansion Cohort must have one of the following advanced or recurrent malignancies: cutaneous melanoma showing primary progression following treatment with an anti-programmed cell death (PD) or anti-PDL1 regimen; or anti-PD1 or anti-PD-L1 treatment-naïve colorectal or gastric cancer, including gastroesophageal junction cancer of Siewert Type II and Type III.
Participants in the Combination Expansion Cohorts must have one of the following advanced or recurrent malignancies: non-small cell lung adenocarcinoma or cutaneous melanoma showing primary progression following treatment with an anti-PD1 or anti-PD-L1 regimen; or anti-PD1 or anti-PD-L1 treatment-naïve colorectal or gastric cancer, including gastroesophageal junction cancer of Siewert Type II and Type III.
Has received prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, or anti-PD-L2 agent
Prior exposure to ALK receptor tyrosine kinase inhibitor, anti-PD1, anti-PDL1 or any drug targeting T-cell checkpoint pathways.
Must have received either nivolumab or pembrolizumab or a different IND-approved anti-PD1 or anti-PD-L1 therapy, unless medically contraindicated
Previous treatment with anti-CD27 antibody, ipilimumab or other anti-CTLA-4 targeted therapies. Previous therapy with other checkpoint blockers such as anti-PD-1 or anti-PD-L1 is acceptable, unless treatment was discontinued for intolerance.
Prior exposure to immunotherapy (either as a single agent or in combination) including but not limited to CD137 or OX40 agonists, anti-CTLA-4, anti-PD-1, or anti-PD-L1, anti-PD-L2 antibody or pathway-targeting agents
Prior EGFR-targeted regimen, anti-HER2, anti-HER3, or anti-HER4 therapy
Prior treatment with anti-PD-1, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), or anti-PD-L1 therapeutic antibody or pathway-targeting agents
Prior treatment with an anti-PD-1, anti-PD-L1, or anti-PD-L2 antibody; neuroblastoma (NB)-patients who have received prior anti-cytotoxic T-lymphocyte antigen (CTLA)-4 antibody therapy are eligible assuming such therapy was discontinued within 28 days of enrollment
Prior immunotherapy with IL-2, IFN-?, or an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or CTLA 4 antibody (including ipilimumab), or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or CTLA-4 antibody.
Subjects who are treatment-naive or pretreated (prior anti-PD-1 or anti-PD-L1 required) in the recurrent/metastatic setting.
Prior therapy for melanoma with the following exceptions which are allowed: 1) surgery for the melanoma lesion(s), 2) adjuvant RT after neurosurgical resection for CNS lesions, and 3) prior adjuvant IFN (see qualifier below). Specifically, patients who received prior therapy with anti-PD-1, anti PD L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T cell costimulation or checkpoint pathways) are not eligible. • Prior treatment with adjuvant IFN is allowed if completed ? 3 months prior to treatment.
Recipient of any blood product and immunotherapy (such as anti-PD1, anti-PDL-1 and anti-CTLA4) within 3 months of enrollment;
Prior treatment with ibrutinib or other BTK inhibitor anti-CD137 or CTLA-4 antibody. The following are exceptions to this criterion: Subjects previously treated with an anti-PD1, anti-PD-L1, or anti-PD-L2 antibody.
Prior exposure to immunotherapy, such as, but not limited to, other anti-CTLA-4, anti-PD-1, or anti-PD-L1 antibodies, excluding therapeutic cancer vaccines
Patients who have received prior anti-CTLA4 or anti-PD1 therapy less than 8 weeks prior to enrollment
Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
In the NSCLC CIT-Naïve expansion cohort in Phase 1b, prior treatment with anti-PD?L1/PD-1 and/or anti-CTLA-4 (investigational or approved) is not allowed
Prior treatment with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
No prior exposure to immune-mediated therapy defined as prior exposure to T-cell and natural killer cell directed therapy (e.g., anti-PD-1, anti-PD-L1, anti-CD137, and anti-CTLA4, etc).
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2
Patient must have had prior treatment with anti-PD-1 or anti-PD-L1 agents and have documented disease progression on these agents prior to registration; patient must have received anti-PD-1 or PD-L1 based therapy as the immediate previous line of treatment and within 56 days prior to registration
Participants with a history of treatment with an anti-PD-1, anti-PD-L1, anti-CTLA-4 or other investigational agents that target immune checkpoint inhibitors
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Prior treatment with CD137 agonists, anti- cytotoxic T-lymphocyte-associated protein 4, anti-PD-1, or anti-PDL1 therapeutic antibody or pathway targeting agents; prior IFN alpha or IL-2 is allowed following 4 week washout from treatment end date
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic\r\nT-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Chemotherapy, or immunotherapy or any other systemic anticancer therapy =< 3 weeks prior to study drug administration date; patients receiving anti-PD-1 treatment, and continue to receiving this treatment in combination with selinexor (Arms L and M), can start receiving the selinexor and anti-PD-1 combination without washout of the prior anti-PD-1 antibody
Prior treatment with cluster of differentiation (CD) 137 agonists or immune checkpoint blockade therapies, anti PD1, and anti-PD-L1 therapeutic antibody
Prior treatment with checkpoint inhibitors and other immunotherapy treatments, including anti-LAG-3, anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibodies, if less than 5 half lives before study drug administration
Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti CTLA 4, or anti-CD38 antibody, or allogeneic stem cell transplantation
Has received prior therapy with an anti-programmed cell death protein 1 (PD-1), anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior systemic chemotherapy within 2 weeks of planed anti-PD1 treatment.
Histologically or cytologically documented cancer to which anti-PD1 or anti-PDL1 are approved therapies
History of prior treatment with immune checkpoint antibodies (e.g. anti-PD1, anti-PDL1, anti-CTLA4 antibody) or co-stimulatory agonist antibodies (e.g. anti-41BB, anti-OX40)\r\n* Prior intravesical treatment with Bacillus Calmette-Guerin (BCG) is allowed; however, the last dose must be at least 6 weeks from time of enrollment and patients must have documented progressive disease at least 6 weeks from completion of last BCG
Patients that plan to receive off-label use of anti-PD1 or anti-PDL1
Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Prior treatment with an anti-HER3 antibody
Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Prior treatment with CD137 agonists, anti?PD-1, or anti?PD-L1 therapeutic antibody or pathway-targeting agents
Subjects who are currently receiving treatment with the anti-PD-1 antibody Pembrolizumab either alone or in combination and are progressing. Subjects must have received at least 4 doses of anti-PD-1/PD-L1 therapy OR
Patients must not have had prior exposure to any immune checkpoint inhibitors including anti-PD-1, anti-PD-L1 gents, anti-PD-L2 agents, or anti-CTLA-4 monoclonal antibodies
Patients who have previously received anti-PD1 or anti-PD-L1 therapy; patients who have previously received anti-CTLA-4 therapy (e.g. ipilimumab) are eligible for study
Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Prior therapy with any antibody/drug that targets the T cell coregulatory proteins, including but not limited to, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-OX-40,and anti-CD40 antibodies. However, half the patients must have progressed on anti Cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA4) monoclonal antibody therapy
Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody (or any other antibody targeting T-cell co-stimulation pathways).
Prior treatment with PD-L1 inhibitor, PD-1 inhibitor, anti-CTLA4, anti-CD137, anti-OX40 or other immune checkpoint blockade or activator therapy with the exception of subjects who received atezolizumab in this study and are eligible for re-treatment
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Patients should be excluded if they have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Prior treatment with CD137 agonists, anti-CTLA-4, anti-programmed death-1 (PD-1), or anti-PD-L1 therapeutic antibody or pathway-targeting agents
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-cluster of differentiation (CD)137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
Has received prior therapy with an anti-programmed cell death-1 (anti-PD-1), anti-PD-ligand 1 (anti-PD-L1), anti-PD-L2, anti-CD137, or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody (including ipilimumab) or OX-40 (Tumor necrosis factor receptor superfamily, member 4 [TNFRSF4]), or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-cluster of differentiation (CD)137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
